Flash of hope: millisecond radiation could spare healthy skin in cancer fight

NCT ID NCT07455331

Not yet recruiting Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of radiation called FLASH therapy, which delivers the entire dose in milliseconds instead of minutes. The goal is to see if it can treat skin cancers (squamous cell and basal cell carcinomas) just as well as standard radiation but with fewer side effects on healthy skin. About 60 people aged 60 or older who cannot have or decline surgery will receive either FLASH or conventional radiation, and researchers will monitor side effects and tumor control for one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FLASH radiotherapy (ultra-fast radiation delivered in milliseconds)
What this could lead to: If successful, FLASH radiotherapy could offer a quicker, less damaging treatment for skin cancers, reducing side effects on healthy tissue while still curing the cancer.
What could go wrong: This is an early phase II trial with only 60 participants, so results may not apply to everyone. FLASH is experimental and its long-term safety and effectiveness compared to standard care are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA (BCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin neoplasm skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA (BCC) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institut Jules Bordet

Brussels, Anderlecht, 1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.